IL23A and psoriasis vulgaris: In line with this, guselkumab and risankizumab—monoclonal antibodies targeting the p19 subunit specific to IL-23—have demonstrated superior clinical efficacy in patients with moderate-to-severe plaque psoriasis compared to ustekinumab [45,46].